Avadel Pharmaceuticals PLC (AVDL) Fundamental Analysis & Valuation

NASDAQ:AVDL • IE00BDGMC594

Current stock price

21.64 USD
+0.01 (+0.05%)
At close:
21.65 USD
+0.01 (+0.05%)
After Hours:

This AVDL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. AVDL Profitability Analysis

1.1 Basic Checks

  • In the past year AVDL has reported negative net income.
  • In the past year AVDL had a positive cash flow from operations.
  • In the past 5 years AVDL reported 4 times negative net income.
  • In the past 5 years AVDL always reported negative operating cash flow.
AVDL Yearly Net Income VS EBIT VS OCF VS FCFAVDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

  • AVDL has a better Return On Assets (-0.14%) than 77.49% of its industry peers.
  • Looking at the Return On Equity, with a value of -0.28%, AVDL is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
Industry RankSector Rank
ROA -0.14%
ROE -0.28%
ROIC N/A
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVDL Yearly ROA, ROE, ROICAVDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Gross Margin of AVDL (91.09%) is better than 92.67% of its industry peers.
  • In the last couple of years the Gross Margin of AVDL has grown nicely.
  • AVDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
AVDL Yearly Profit, Operating, Gross MarginsAVDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. AVDL Health Analysis

2.1 Basic Checks

  • AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AVDL has more shares outstanding
  • The number of shares outstanding for AVDL has been increased compared to 5 years ago.
  • Compared to 1 year ago, AVDL has a worse debt to assets ratio.
AVDL Yearly Shares OutstandingAVDL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVDL Yearly Total Debt VS Total AssetsAVDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 7.90 indicates that AVDL is not in any danger for bankruptcy at the moment.
  • AVDL has a better Altman-Z score (7.90) than 81.15% of its industry peers.
  • The Debt to FCF ratio of AVDL is 1.80, which is an excellent value as it means it would take AVDL, only 1.80 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.80, AVDL belongs to the top of the industry, outperforming 95.29% of the companies in the same industry.
  • A Debt/Equity ratio of 0.35 indicates that AVDL is not too dependend on debt financing.
  • AVDL has a Debt to Equity ratio of 0.35. This is comparable to the rest of the industry: AVDL outperforms 40.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.8
Altman-Z 7.9
ROIC/WACCN/A
WACC7.87%
AVDL Yearly LT Debt VS Equity VS FCFAVDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • A Current Ratio of 2.76 indicates that AVDL has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.76, AVDL is in line with its industry, outperforming 48.69% of the companies in the same industry.
  • AVDL has a Quick Ratio of 2.37. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
  • AVDL has a Quick ratio (2.37) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.37
AVDL Yearly Current Assets VS Current LiabilitesAVDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. AVDL Growth Analysis

3.1 Past

  • AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.
  • AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.88%.
  • AVDL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.35% yearly.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%

3.2 Future

  • The Earnings Per Share is expected to grow by 39.72% on average over the next years. This is a very strong growth
  • AVDL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.44% yearly.
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y39.72%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y24.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
AVDL Yearly Revenue VS EstimatesAVDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
AVDL Yearly EPS VS EstimatesAVDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

4

4. AVDL Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Forward Earnings ratio of 26.23 indicates a quite expensive valuation of AVDL.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AVDL indicates a somewhat cheap valuation: AVDL is cheaper than 73.82% of the companies listed in the same industry.
  • AVDL's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.12.
Industry RankSector Rank
PE N/A
Fwd PE 26.23
AVDL Price Earnings VS Forward Price EarningsAVDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • AVDL's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AVDL is cheaper than 76.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 101.28
EV/EBITDA N/A
AVDL Per share dataAVDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as AVDL's earnings are expected to grow with 64.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.39%
EPS Next 3Y64.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVDL Dividend Analysis

5.1 Amount

  • AVDL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVDL Fundamentals: All Metrics, Ratios and Statistics

Avadel Pharmaceuticals PLC

NASDAQ:AVDL (2/11/2026, 8:07:16 PM)

After market: 21.65 +0.01 (+0.05%)

21.64

+0.01 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-09
Inst Owners95.18%
Inst Owner Change-0.62%
Ins Owners1.06%
Ins Owner Change-15.72%
Market Cap1.96B
Revenue(TTM)248.52M
Net Income(TTM)-278.00K
Analysts70
Price Target21.48 (-0.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.03%
Min EPS beat(2)-100%
Max EPS beat(2)258.07%
EPS beat(4)2
Avg EPS beat(4)42.28%
Min EPS beat(4)-100%
Max EPS beat(4)258.07%
EPS beat(8)4
Avg EPS beat(8)22.06%
EPS beat(12)4
Avg EPS beat(12)-2.88%
EPS beat(16)5
Avg EPS beat(16)-12.25%
Revenue beat(2)2
Avg Revenue beat(2)5.92%
Min Revenue beat(2)3.23%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)3.03%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.61%
Revenue beat(8)7
Avg Revenue beat(8)3.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.63%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.23
P/S 7.89
P/FCF 101.28
P/OCF 56.74
P/B 19.96
P/tB 24.08
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.83
Fwd EY3.81%
FCF(TTM)0.21
FCFY0.99%
OCF(TTM)0.38
OCFY1.76%
SpS2.74
BVpS1.08
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.14%
ROE -0.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.09%
FCFM 7.79%
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.8
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.76
Quick Ratio 2.37
Altman-Z 7.9
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y39.72%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y24.44%
EBIT growth 1Y92.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.2%
EBIT Next 3Y69.86%
EBIT Next 5Y44.48%
FCF growth 1Y116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.82%
OCF growth 3YN/A
OCF growth 5YN/A

Avadel Pharmaceuticals PLC / AVDL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Avadel Pharmaceuticals PLC?

ChartMill assigns a fundamental rating of 5 / 10 to AVDL.


What is the valuation status of Avadel Pharmaceuticals PLC (AVDL) stock?

ChartMill assigns a valuation rating of 4 / 10 to Avadel Pharmaceuticals PLC (AVDL). This can be considered as Fairly Valued.


How profitable is Avadel Pharmaceuticals PLC (AVDL) stock?

Avadel Pharmaceuticals PLC (AVDL) has a profitability rating of 3 / 10.


What is the financial health of Avadel Pharmaceuticals PLC (AVDL) stock?

The financial health rating of Avadel Pharmaceuticals PLC (AVDL) is 7 / 10.